quarta-feira, 18 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· June 4, 2026

GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE

View original at globenewswire.com
GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases Foster City, Calif…
Opening lines of the source · short snapshot: read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Gamgertamig is a potential first-in-class and best-in-class T cell engager in autoimmune diseases

    60% confidence
  • Gamgertamig is expected to enter registrational studies as early as 2027

    60% confidence
  • Gamgertamig is designed to enable rapid and deep plasma cell and B cell depletion following a limited subcutaneously administered treatment course with the potential to induce durable disease control in severe antibody-mediated orphan diseases

    60% confidence
  • Gilead operates in more than 35 countries worldwide

    60% confidence
  • Lakefront's year-end 2026 cash balance is expected to be approximately €2 billion

    60% confidence
  • Following the transaction, Lakefront will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities

    60% confidence
  • The acquisition builds on Gilead's long-term strategy to shift treatment paradigms from chronic disease management toward the potential for durable immune reset

    60% confidence